Total Payments
$83,014
2024 Payments
$20,536
Companies
10
Transactions
49
Medicare Patients
989
Medicare Billing
$66,726
Payment Breakdown by Category
Consulting$61,190 (73.7%)
Other$20,380 (24.6%)
Travel$801.23 (1.0%)
Food & Beverage$642.42 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,190 | 28 | 73.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,380 | 2 | 24.6% |
| Travel and Lodging | $801.23 | 5 | 1.0% |
| Food and Beverage | $642.42 | 14 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22,374 | 20 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $21,129 | 13 | $0 (2024) |
| Janssen Research & Development, LLC | $18,063 | 8 | $0 (2024) |
| Eli Lilly and Company | $17,500 | 1 | $0 (2020) |
| CSL Behring | $3,695 | 1 | $0 (2023) |
| Almirall LLC | $105.81 | 1 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $70.86 | 2 | $0 (2018) |
| Mallinckrodt LLC | $38.96 | 1 | $0 (2017) |
| Incyte Corporation | $23.13 | 1 | $0 (2022) |
| Janssen Biotech, Inc. | $14.34 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,536 | 13 | Novartis Pharmaceuticals Corporation ($7,673) |
| 2023 | $12,020 | 8 | CSL Behring ($3,695) |
| 2022 | $2,815 | 5 | Merck Sharp & Dohme LLC ($2,792) |
| 2021 | $11,220 | 4 | Novartis Pharmaceuticals Corporation ($10,620) |
| 2020 | $26,510 | 7 | Eli Lilly and Company ($17,500) |
| 2019 | $3,279 | 4 | Merck Sharp & Dohme Corporation ($3,173) |
| 2018 | $70.86 | 2 | Regeneron Healthcare Solutions, Inc. ($70.86) |
| 2017 | $6,564 | 6 | Merck Sharp & Dohme Corporation ($6,525) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $5,362.50 | General |
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| 11/06/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.84 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $200.64 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $158.85 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $65.50 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $40.31 | General |
| 06/14/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $378.36 | General |
| 05/17/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $4.93 | General |
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 11/20/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 11/02/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Immunology | ||||||
| 10/13/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $35.44 | General |
| Category: Dermatology | ||||||
| 09/01/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 07/25/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 06/06/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 05/18/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 02/13/2023 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $3,695.00 | General |
| 11/30/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/15/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 06/22/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 03/27/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.13 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 247 | 476 | $58,816 | $16,083 |
| 2022 | 7 | 228 | 403 | $42,252 | $14,839 |
| 2021 | 11 | 287 | 490 | $62,794 | $20,869 |
| 2020 | 9 | 227 | 430 | $54,925 | $14,935 |
Total Patients
989
Total Services
1,799
Medicare Billing
$66,726
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 54 | 76 | $12,717 | $5,557 | 43.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $10,746 | $2,920 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 42 | 58 | $5,394 | $2,661 | 49.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 41 | 61 | $12,505 | $2,430 | 19.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 21 | $4,368 | $1,379 | 31.6% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 21 | 26 | $3,380 | $463.47 | 13.7% |
| 11104 | Punch biopsy, first skin growth | Facility | 2023 | 11 | 11 | $3,630 | $395.24 | 10.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2023 | 36 | 196 | $6,076 | $276.32 | 4.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 93 | $13,555 | $7,116 | 52.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 40 | 55 | $11,275 | $2,355 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 42 | 49 | $4,557 | $2,133 | 46.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 23 | $3,243 | $1,359 | 41.9% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 16 | 16 | $2,960 | $1,339 | 45.2% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2022 | 14 | 15 | $1,950 | $277.27 | 14.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2022 | 32 | 152 | $4,712 | $258.88 | 5.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 101 | $14,395 | $7,934 | 55.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 53 | 74 | $6,882 | $3,973 | 57.7% |
| 17000 | Destruction of skin growth | Facility | 2021 | 39 | 60 | $12,300 | $2,436 | 19.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $4,830 | $1,726 | 35.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 24 | $3,309 | $1,458 | 44.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 11 | 11 | $2,035 | $943.36 | 46.4% |
| 17110 | Destruction of up to 14 skin growths | Facility | 2021 | 12 | 13 | $5,993 | $686.52 | 11.5% |
| 11104 | Punch biopsy of single skin lesion | Facility | 2021 | 15 | 15 | $4,077 | $552.69 | 13.6% |
| 11102 | Tangential biopsy of single skin lesion | Facility | 2021 | 21 | 26 | $3,380 | $539.13 | 16.0% |
| 11900 | Injection of up to 7 skin growths | Facility | 2021 | 14 | 19 | $1,501 | $412.67 | 27.5% |
About Dr. Misha Rosenbach, MD
Dr. Misha Rosenbach, MD is a Internal Medicine healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659421790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Misha Rosenbach, MD has received a total of $83,014 in payments from pharmaceutical and medical device companies, with $20,536 received in 2024. These payments were reported across 49 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($61,190).
As a Medicare-enrolled provider, Rosenbach has provided services to 989 Medicare beneficiaries, totaling 1,799 services with total Medicare billing of $66,726. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Philadelphia, PA
- Active Since 01/11/2007
- Last Updated 11/28/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1659421790
Products in Payments
- COSENTYX (Biological) $7,380
- MK-1654 (Drug) $500.00
- DUPIXENT DUPILUMAB INJECTION (Biological) $70.86
- ACTHAR (Biological) $38.96
- COSENTYX (Drug) $35.44
- OPZELURA (Drug) $23.13
- TREMFYA (Drug) $14.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Philadelphia
Pitamber Devgon, Md, MD
Internal Medicine — Payments: $7.5M
Internal Medicine $7.5M
Dr. David Horn, M.d, M.D
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Daniel Rader, Md, MD
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Corey Langer, Md, MD
Internal Medicine — Payments: $742,647
Internal Medicine $742,647
Dr. Intekhab Ahmed, M.d, M.D
Internal Medicine — Payments: $621,997
Internal Medicine $621,997
David Goldmann, Md, MD
Internal Medicine — Payments: $587,696
Internal Medicine $587,696